Eosinophilic asthma accounts for 40% to 50% of asthmatic patients. However, 5% to 10% of patients with asthma need high-dose drug control, which is clinically referred to as severe asthma patients. Interleukin (IL)-5 plays an important role in the proliferation, maturation, and migration of eosinophils. Benralizumab, as an antagonist of the IL-5 receptor, can treat eosinophilic asthma by promoting the apoptosis of eosinophils. The implications for efficacy and/or adverse events are unclear. This article reviews the findings about benralizumab in the treatment of severe eosinophilic asthma in recent years. Results indicated the effectiveness of benralizumab for the treatment of severe asthma.
Interleukin-27 receptor (IL-27R) is expressed in a variety of immune cells and structural cells, including dendritic cells. The mechanism of IL-27 in asthma has not been fully elucidated. This study aimed to examine whether IL-27 regulated the CD39/ATP axis of dendritic cells in asthma. Our results showed that in ovalbumin (OVA)-induced asthma mouse model, IL-27Rα−/− asthmatic mice showed increased airway resistance, increased infiltration of inflammatory cells in lung tissue, proliferation of goblet cells, enhanced expression of Muc5 AC around airway epithelium, increased total number of cells and eosinophils, increased levels of total IgE, OVA-IgE, IL-4, IL-5, IL-13 and IL-17 A, and increased expression of transcription factors GATA-3 and RORγt in lung tissue. The expression of CD39 mRNA and protein in the lung tissue of IL-27Rα−/− asthmatic mice decreased, and the expression of NLRP3, ASC and Caspase-1 in NLRP3 inflammasome components increased. The concentration of ATP was significantly increased compared with WT asthmatic mice. In vitro experiments showed that the expression of CD39 in lung dendritic cells of IL-27Rα−/− asthmatic mice decreased, while the expression of NLRP3 inflammasome components NLRP3, ASC and Caspase-1 increased. These findings indicate that IL-27 directly and indirectly regulates immunoinflammatory responses in asthma by acting on dendritic cells CD39/ATP Axis.
26 February 2025 in The Clinical Respiratory Journal
Background: Tuberculous pericarditis begins with fibrinous and hemorrhagic pericarditis, followed by pericardial effusion, then pericardial hypertrophy, which may turn into subacute or chronic stage, and partly develop into pericarditis. Early diagnosis and treatment have very important clinical significance.Case Summary: We present a case of an 82‐year‐old man with a known history of hypertension who was admitted for pleural effusion. CT scan of the chest showed findings of pleural effusion. An echocardiographic study during admission revealed a small amount of pericardial effusion (~1.2 cm in thickness). A whole‐body positron emission tomography‐computer tomography (PET‐CT) scan was then performed and showed a slightly increased fluorodeoxyglucose uptake in the entire pericardium considering tuberculosis. He was started on antituberculosis (TB) medications and tolerated them well. Follow‐up echocardiographic study showed no re‐accumulation of pleural effusion and pericardial fluid.Conclusion: Transudative–exudative pleural effusion may be one of the clinical manifestations of tuberculous pericarditis. (1) Bilateral leaking pleural effusion may be the early clinical manifestation of tuberculous pericarditis; (2) PET/CT in the diagnosis and efficacy evaluation of tuberculous pericarditis is valuable; and (3) the central venous pressure may be an indicator of choice for treatment of tuberculous pericarditis.
BACKGROUND Cough variant asthma (CVA) is a prevalent but underdiagnosed subtype of chronic cough, largely due to the limited accessibility of pulmonary function tests in primary care. OBJECTIVE This study aimed to develop and prospectively validate an interpretable machine learning model using routine laboratory data to facilitate accessible CVA screening. METHODS We conducted a multicenter study combining retrospective model development and prospective validation using data from January 2021 to August 2025. The study included 3 sets—a retrospective development set (n=533; 428 training and 105 internal testing) and 2 prospective validation sets (internal validation: n=59 and external validation: n=78). In total, 54 routine biochemical, coagulation, and hematological markers were analyzed. A Tabular Prior-Data Fitted Network (TabPFN) model was developed and benchmarked against extreme gradient boosting (XGBoost). Performance was evaluated via area under the curve (AUC), accuracy, and specificity. Shapley Additive Explanations (SHAP) and decision curve analysis (DCA) were used to assess interpretability and clinical utility. RESULTS In external validation, TabPFN achieved an AUC of 0.858 (95% CI 0.763-0.943), accuracy of 79.5%, sensitivity of 71.4%, and specificity of 86%. XGBoost achieved a higher external AUC of 0.912 (95% CI 0.842-0.982) and sensitivity of 91.4%, but lower accuracy (75.6%) and specificity (62.8%) at the fixed 0.5 probability threshold. TabPFN retained higher AUCs than XGBoost in internal testing (0.964 vs 0.890) and temporal validation (0.925 vs 0.846). DCA demonstrated that TabPFN provided higher net benefit across clinically relevant threshold probabilities, with the range varying across validation cohorts. SHAP analysis identified serum sodium (Na) and prothrombin time international normalized ratio as the leading predictors, followed jointly by mean corpuscular hemoglobin concentration and red cell distribution width-SD, which showed the same rounded mean absolute SHAP value at the reported 2-decimal precision, and elevated sodium levels (>141 mmol/L) were associated with increased predicted risk. CONCLUSIONS The TabPFN model demonstrated robust prospective performance as an accessible screening tool for CVA, with balanced threshold-dependent classification performance across validation cohorts. Although TabPFN showed higher discrimination than XGBoost in internal and temporal validation, XGBoost achieved a higher AUC in the external cohort, indicating that neither model uniformly outperformed the other across all performance dimensions.
Objective: To delineate the demographic, clinical, and radiological features of immunocompetent patients with pulmonary cryptococcosis (PC) who test negative for serum cryptococcal antigen (CrAg), a subgroup that poses a diagnostic challenge. Methods: Participants were stratified into CrAg-positive (n = 128) and CrAg-negative (n = 71) cohorts. Comparative analyses were performed on clinical presentation, chest computed tomography (CT) imaging features, and laboratory parameters. Results: Patients with false-negative CrAg results were more likely to be asymptomatic (46.5% vs. 20.3% in the CrAg-positive group; p < 0.05). Their chest CT scans typically revealed solitary pulmonary nodules, frequently unilateral and located in the right lung, with a notable absence of pleural effusion or lymphadenopathy. Laboratory findings in the CrAg-negative group were characterized by a lower neutrophil ratio and erythrocyte sedimentation rate. Furthermore, higher CrAg titers were significantly correlated with the presence of respiratory symptoms, specific CT signs (e.g., air bronchogram, lymphadenopathy), and elevated systemic inflammatory markers. Conclusions: False-negative serum CrAg in immunocompetent PC patients is characterized by an asymptomatic presentation and a solitary nodule on imaging, with normal laboratory parameters. CrAg titers may reflect disease severity and warrant prospective evaluation as a potential biomarker for guiding antifungal therapy.
Background: Cough variant asthma (CVA) is a prevalent but underdiagnosed subtype of chronic cough, largely due to the limited accessibility of pulmonary function tests in primary care. Objective: This study aimed to develop and prospectively validate an interpretable machine learning model using routine laboratory data to facilitate accessible CVA screening. Methods: We conducted a multicenter study combining retrospective model development and prospective validation using data from January 2021 to August 2025. The study included 3 sets—a retrospective development set (n=533; 428 training and 105 internal testing) and 2 prospective validation sets (internal validation: n=59 and external validation: n=78). In total, 54 routine biochemical, coagulation, and hematological markers were analyzed. A Tabular Prior-Data Fitted Network (TabPFN) model was developed and benchmarked against extreme gradient boosting (XGBoost). Performance was evaluated via area under the curve (AUC), accuracy, and specificity. Shapley Additive Explanations (SHAP) and decision curve analysis (DCA) were used to assess interpretability and clinical utility. Results: In external validation, TabPFN achieved an AUC of 0.858 (95% CI 0.763-0.943), accuracy of 79.5%, sensitivity of 71.4%, and specificity of 86%. XGBoost achieved a higher external AUC of 0.912 (95% CI 0.842-0.982) and sensitivity of 91.4%, but lower accuracy (75.6%) and specificity (62.8%) at the fixed 0.5 probability threshold. TabPFN retained higher AUCs than XGBoost in internal testing (0.964 vs 0.890) and temporal validation (0.925 vs 0.846). DCA demonstrated that TabPFN provided higher net benefit across clinically relevant threshold probabilities, with the range varying across validation cohorts. SHAP analysis identified serum sodium (Na) and prothrombin time international normalized ratio as the leading predictors, followed jointly by mean corpuscular hemoglobin concentration and red cell distribution width-SD, which showed the same rounded mean absolute SHAP value at the reported 2-decimal precision, and elevated sodium levels (>141 mmol/L) were associated with increased predicted risk. Conclusions: The TabPFN model demonstrated robust prospective performance as an accessible screening tool for CVA, with balanced threshold-dependent classification performance across validation cohorts. Although TabPFN showed higher discrimination than XGBoost in internal and temporal validation, XGBoost achieved a higher AUC in the external cohort, indicating that neither model uniformly outperformed the other across all performance dimensions.